Evidence map›Paper›PMID 42249939›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Real-world outcomes of [

Giulia Santo, Gianpaolo di Santo, Ariane Kronthaler, Mohsen Farsad, Lisa Maria Rossetti, Peter Lehmann, Fabian Scherbauer, Francesco Cicone, Irene J Virgolini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Immune Checkpoint Blockade Enhances the Abscopal Effect of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoid.European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giulia SantoDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria. giulia.santo@i-med.ac.at.ORCID 0000-0001-6565-0686
Gianpaolo di SantoDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Ariane KronthalerDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.ORCID 0009-0007-9442-6158
Mohsen FarsadDepartment of Nuclear Medicine, Central Hospital of Bolzano, Bozen, Italy.ORCID 0000-0002-7596-6948
Lisa Maria RossettiDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Peter LehmannDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Fabian ScherbauerDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria.
Francesco CiconeNuclear Medicine Unit, Department of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.ORCID 0000-0003-4664-1965
Irene J VirgoliniDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria. irene.virgolini@i-med.ac.at.ORCID 0000-0001-7097-6170

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known about predictors of response to radionuclide therapy with PSMA-ligands in patients with [

methodsmCRPC patients who underwent [

resultsTwenty-five [

conclusionsOur preliminary results suggest that a whole-body [

Indexed as

DipeptidesFluorodeoxyglucose F18LutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesAgedAged, 80 and overHeterocyclic Compounds, 1-RingHumansMaleMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyProstate-Specific AntigenRadiopharmaceuticalsRetrospective StudiesDipeptidesFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingLutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsFDGmCRPCPSMARadioligand therapyTreatment response

Identifiers

PMID42249939
PMCPMC13526135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.